CAB-101/CABA-201
Cancer
Dermatology
Immunology
Autoimmune
Adult Subjects
Female Subjects
Male Subjects
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris